3Miner P Jr,Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo - controlled trial[J]. Am J Gastroenterol.2002.97 : 1332-1339.
4Habu Y, Fukui Y, Maruno T, et al. Cost-effectiveness analysis for the treatment of non-erosive reflux disease [ J ], Nippon Rinsho, 2007,65(5) :951 - 955.
5Ishino Y, Sugano K. Acid-suppressive strategy against gastroeso-phageal reflux diseases and non-erosive reflux diseases: the alternative of proton-pump inhibitors or H2 receptor antagonists[J]. Nippon Rinsho. 2007,65(5) :891 - 894.
6Carmagnola S, Fraquelli M, Cantu P, et al. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease [J]. Scand J Gastroenterol,2006,41(7) :767 - 772.
7Konturek JW, Beneke M, Koppermann R. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial [ J ]. Med Sci Monit, 2007,13 ( 1 ) : 44 - 49.
8Dettmar PW, Hampson FC, Taubel J, et al. The suppression of gastro-oesophageal reflux by alginates[-J]. Int J Clin Pract, 2007,61 (10) :1654 - 1662.
9Dettmar PW, Sykes J, Little SL, et al. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes[J]. Int J Clin Pract,2006,60(3) :275 - 278.
10Tonini M,De Giorgio R,De Ponti F. Progress with novel pharma- cological strategies for gastro-oesophageal reflux disease[ J ]. Drugs, 2004,64(4) :347 - 361.
8Dzhula G S, Sekareva E V.Clinical and endoscopic characteristics of esophagitis and emotionally-personal sphere of patients with gastro esophageal reflux disease[J].Eksp Klin Gastroenterol, 2009, 4(5) : 35-39.
10Shaw MJ,Talley NJ,Beebe TJ,et al.Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. American Journal of Gastroenterology . 2001
